Research ArticleArticle
Evaluation of 89 Compounds for Identification of Substrates for Cynomolgus Monkey CYP2C76, a New Bupropion/Nifedipine Oxidase
Shinya Hosaka, Norie Murayama, Masahiro Satsukawa, Makiko Shimizu, Shotaro Uehara, Hideki Fujino, Kazuhide Iwasaki, Shunsuke Iwano, Yasuhiro Uno and Hiroshi Yamazaki
Drug Metabolism and Disposition January 2015, 43 (1) 27-33; DOI: https://doi.org/10.1124/dmd.114.061275
Shinya Hosaka
Laboratory of Drug Metabolism and Pharmacokinetics, Showa Pharmaceutical University, Tokyo, Japan (S.H., N.M., M.Shi., S.U., S.I., H.Y.); Pharmacokinetics and Safety Research Department, Kaken Pharmaceutical Co., Ltd., Shizuoka, Japan (S.H., M.Sa.); School of Pharmacy, Hyogo University of Health Sciences, Kobe, Japan (H.F.); Novartis Pharma K.K., Tokyo, Japan (S.I.); and Pharmacokinetics and Bioanalysis Center, Shin Nippon Biomedical Laboratories, Ltd., Kainan, Japan (K.I., Y.U.)
Norie Murayama
Laboratory of Drug Metabolism and Pharmacokinetics, Showa Pharmaceutical University, Tokyo, Japan (S.H., N.M., M.Shi., S.U., S.I., H.Y.); Pharmacokinetics and Safety Research Department, Kaken Pharmaceutical Co., Ltd., Shizuoka, Japan (S.H., M.Sa.); School of Pharmacy, Hyogo University of Health Sciences, Kobe, Japan (H.F.); Novartis Pharma K.K., Tokyo, Japan (S.I.); and Pharmacokinetics and Bioanalysis Center, Shin Nippon Biomedical Laboratories, Ltd., Kainan, Japan (K.I., Y.U.)
Masahiro Satsukawa
Laboratory of Drug Metabolism and Pharmacokinetics, Showa Pharmaceutical University, Tokyo, Japan (S.H., N.M., M.Shi., S.U., S.I., H.Y.); Pharmacokinetics and Safety Research Department, Kaken Pharmaceutical Co., Ltd., Shizuoka, Japan (S.H., M.Sa.); School of Pharmacy, Hyogo University of Health Sciences, Kobe, Japan (H.F.); Novartis Pharma K.K., Tokyo, Japan (S.I.); and Pharmacokinetics and Bioanalysis Center, Shin Nippon Biomedical Laboratories, Ltd., Kainan, Japan (K.I., Y.U.)
Makiko Shimizu
Laboratory of Drug Metabolism and Pharmacokinetics, Showa Pharmaceutical University, Tokyo, Japan (S.H., N.M., M.Shi., S.U., S.I., H.Y.); Pharmacokinetics and Safety Research Department, Kaken Pharmaceutical Co., Ltd., Shizuoka, Japan (S.H., M.Sa.); School of Pharmacy, Hyogo University of Health Sciences, Kobe, Japan (H.F.); Novartis Pharma K.K., Tokyo, Japan (S.I.); and Pharmacokinetics and Bioanalysis Center, Shin Nippon Biomedical Laboratories, Ltd., Kainan, Japan (K.I., Y.U.)
Shotaro Uehara
Laboratory of Drug Metabolism and Pharmacokinetics, Showa Pharmaceutical University, Tokyo, Japan (S.H., N.M., M.Shi., S.U., S.I., H.Y.); Pharmacokinetics and Safety Research Department, Kaken Pharmaceutical Co., Ltd., Shizuoka, Japan (S.H., M.Sa.); School of Pharmacy, Hyogo University of Health Sciences, Kobe, Japan (H.F.); Novartis Pharma K.K., Tokyo, Japan (S.I.); and Pharmacokinetics and Bioanalysis Center, Shin Nippon Biomedical Laboratories, Ltd., Kainan, Japan (K.I., Y.U.)
Hideki Fujino
Laboratory of Drug Metabolism and Pharmacokinetics, Showa Pharmaceutical University, Tokyo, Japan (S.H., N.M., M.Shi., S.U., S.I., H.Y.); Pharmacokinetics and Safety Research Department, Kaken Pharmaceutical Co., Ltd., Shizuoka, Japan (S.H., M.Sa.); School of Pharmacy, Hyogo University of Health Sciences, Kobe, Japan (H.F.); Novartis Pharma K.K., Tokyo, Japan (S.I.); and Pharmacokinetics and Bioanalysis Center, Shin Nippon Biomedical Laboratories, Ltd., Kainan, Japan (K.I., Y.U.)
Kazuhide Iwasaki
Laboratory of Drug Metabolism and Pharmacokinetics, Showa Pharmaceutical University, Tokyo, Japan (S.H., N.M., M.Shi., S.U., S.I., H.Y.); Pharmacokinetics and Safety Research Department, Kaken Pharmaceutical Co., Ltd., Shizuoka, Japan (S.H., M.Sa.); School of Pharmacy, Hyogo University of Health Sciences, Kobe, Japan (H.F.); Novartis Pharma K.K., Tokyo, Japan (S.I.); and Pharmacokinetics and Bioanalysis Center, Shin Nippon Biomedical Laboratories, Ltd., Kainan, Japan (K.I., Y.U.)
Shunsuke Iwano
Laboratory of Drug Metabolism and Pharmacokinetics, Showa Pharmaceutical University, Tokyo, Japan (S.H., N.M., M.Shi., S.U., S.I., H.Y.); Pharmacokinetics and Safety Research Department, Kaken Pharmaceutical Co., Ltd., Shizuoka, Japan (S.H., M.Sa.); School of Pharmacy, Hyogo University of Health Sciences, Kobe, Japan (H.F.); Novartis Pharma K.K., Tokyo, Japan (S.I.); and Pharmacokinetics and Bioanalysis Center, Shin Nippon Biomedical Laboratories, Ltd., Kainan, Japan (K.I., Y.U.)
Yasuhiro Uno
Laboratory of Drug Metabolism and Pharmacokinetics, Showa Pharmaceutical University, Tokyo, Japan (S.H., N.M., M.Shi., S.U., S.I., H.Y.); Pharmacokinetics and Safety Research Department, Kaken Pharmaceutical Co., Ltd., Shizuoka, Japan (S.H., M.Sa.); School of Pharmacy, Hyogo University of Health Sciences, Kobe, Japan (H.F.); Novartis Pharma K.K., Tokyo, Japan (S.I.); and Pharmacokinetics and Bioanalysis Center, Shin Nippon Biomedical Laboratories, Ltd., Kainan, Japan (K.I., Y.U.)
Hiroshi Yamazaki
Laboratory of Drug Metabolism and Pharmacokinetics, Showa Pharmaceutical University, Tokyo, Japan (S.H., N.M., M.Shi., S.U., S.I., H.Y.); Pharmacokinetics and Safety Research Department, Kaken Pharmaceutical Co., Ltd., Shizuoka, Japan (S.H., M.Sa.); School of Pharmacy, Hyogo University of Health Sciences, Kobe, Japan (H.F.); Novartis Pharma K.K., Tokyo, Japan (S.I.); and Pharmacokinetics and Bioanalysis Center, Shin Nippon Biomedical Laboratories, Ltd., Kainan, Japan (K.I., Y.U.)
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
In this issue
Research ArticleArticle
Novel CYP2C76 Substrates
Shinya Hosaka, Norie Murayama, Masahiro Satsukawa, Makiko Shimizu, Shotaro Uehara, Hideki Fujino, Kazuhide Iwasaki, Shunsuke Iwano, Yasuhiro Uno and Hiroshi Yamazaki
Drug Metabolism and Disposition January 1, 2015, 43 (1) 27-33; DOI: https://doi.org/10.1124/dmd.114.061275
Research ArticleArticle
Novel CYP2C76 Substrates
Shinya Hosaka, Norie Murayama, Masahiro Satsukawa, Makiko Shimizu, Shotaro Uehara, Hideki Fujino, Kazuhide Iwasaki, Shunsuke Iwano, Yasuhiro Uno and Hiroshi Yamazaki
Drug Metabolism and Disposition January 1, 2015, 43 (1) 27-33; DOI: https://doi.org/10.1124/dmd.114.061275
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement